The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study

A randomized, open-label, crossover study to compare the safety and pharmacokinetics of two tablet formulations of tenofovir (tenofovir disoproxil and tenofovir disoproxil fumarate) in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cp203651 ◽

2020 ◽

Vol 58 (12) ◽

pp. 749-756

Author(s):

Jae Nam Yun ◽

Ji-Sun Yeun ◽

Hye-Su Kan ◽

Minyu Lee ◽

Namsick Kim ◽

...

Keyword(s):

Crossover Study ◽

Tenofovir Disoproxil Fumarate ◽

Healthy Subjects ◽

Open Label ◽

Tablet Formulations

Download Full-text

Assessment of Pharmacodynamic Equivalence and Tolerability of Lanthanum Carbonate Oral Powder and Tablet Formulations: A Single-Center, Randomized, Open-Label, 2-Period Crossover Study in Healthy Subjects

Clinical Therapeutics ◽

10.1016/j.clinthera.2012.05.003 ◽

2012 ◽

Vol 34 (6) ◽

pp. 1290-1300.e2 ◽

Cited By ~ 6

Author(s):

David Pierce ◽

Stuart Hossack ◽

Antoine Robinson ◽

Pinggao Zhang ◽

Patrick Martin

Keyword(s):

Crossover Study ◽

Healthy Subjects ◽

Lanthanum Carbonate ◽

Single Center ◽

Open Label ◽

Tablet Formulations

Download Full-text

326 Co-administration of a CYP3A4 inhibitor (ketoconazole) increased the bioavailability of CS-7017 but did not affect tolerability: results from an open-label, phase I, two-way crossover study in healthy subjects

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)72033-4 ◽

2010 ◽

Vol 8 (7) ◽

pp. 104-105

Author(s):

G. Senaldi ◽

H. Zahir ◽

L. He ◽

J.C. Rasmussen ◽

K. Liu ◽

...

Keyword(s):

Phase I ◽

Crossover Study ◽

Healthy Subjects ◽

Cyp3a4 Inhibitor ◽

Open Label ◽

Open Label Phase

Download Full-text

Bioavailability of Three Rufinamide Oral Suspensions Compared With the Marketed 400-mg Tablet Formulation: Results From a Randomized-Sequence, Open-Label, Four-Period, Four-Sequence Crossover Study in Healthy Subjects

Clinical Therapeutics ◽

10.1016/j.clinthera.2011.01.016 ◽

2011 ◽

Vol 33 (1) ◽

pp. 146-157 ◽

Cited By ~ 6

Author(s):

David John Critchley ◽

Jagadeesh Aluri ◽

Peter Boyd ◽

Matthew Whayman ◽

Milind Narurkar ◽

...

Keyword(s):

Crossover Study ◽

Healthy Subjects ◽

Tablet Formulation ◽

Open Label

Download Full-text

T1080 Effects of Rabeprazole Sodium and Ranitidine Hydrochloride On Gastric Acidity for 2 Consecutive Weeks: A Randomized, Open-Label, Two-Way Crossover Study in Healthy Subjects Using BRAVO® Capsules Fixed to the Stomach

Gastroenterology ◽

10.1016/s0016-5085(08)62241-6 ◽

2008 ◽

Vol 134 (4) ◽

pp. A-479

Author(s):

Shoko Ono ◽

Mototsugu Kato ◽

Yuji Ono ◽

Masahiro Asaka

Keyword(s):

Crossover Study ◽

Healthy Subjects ◽

Gastric Acidity ◽

Open Label ◽

Ranitidine Hydrochloride ◽

Rabeprazole Sodium

Download Full-text

An open-label, randomized, crossover study of the relative bioavailability of desvenlafaxine after oral administration of extended-release venlafaxine and sustained-release desvenlafaxine succinate in healthy subjects

Clinical Pharmacology & Therapeutics ◽

10.1016/j.clpt.2004.12.222 ◽

2005 ◽

Vol 77 (2) ◽

pp. P86-P86 ◽

Cited By ~ 1

Author(s):

A NICHOLS ◽

A PATAT ◽

S BAIRDBELLAIRE ◽

J BEHRLE ◽

P CHRETIEN

Keyword(s):

Sustained Release ◽

Oral Administration ◽

Crossover Study ◽

Healthy Subjects ◽

Extended Release ◽

Relative Bioavailability ◽

Open Label ◽

Randomized Crossover Study

Download Full-text

A randomized, open-label, crossover study evaluating bioequivalence of two N-acetylcysteine 2% oral solution formulations in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cp203128 ◽

2018 ◽

Vol 56 (09) ◽

pp. 417-425

Author(s):

Frank Donath ◽

Marianna Armogida ◽

Lucy Shneyer

Keyword(s):

Crossover Study ◽

Healthy Subjects ◽

Oral Solution ◽

Open Label

Download Full-text

An open-label, randomized, single-dose, dose-proportionality study of oral doses of a sustained-release formulation of desvenlafaxine succinate in healthy subjects

Clinical Pharmacology & Therapeutics ◽

10.1016/j.clpt.2004.12.207 ◽

2005 ◽

Vol 77 (2) ◽

pp. P82-P82 ◽

Cited By ~ 4

Author(s):

J BEHRLE ◽

A NICHOLS ◽

S MCGRORY ◽

D RAIBLE

Keyword(s):

Single Dose ◽

Sustained Release ◽

Healthy Subjects ◽

Dose Proportionality ◽

Open Label ◽

Release Formulation ◽

Sustained Release Formulation ◽

Oral Doses

Download Full-text

A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects

Clinical Therapeutics ◽

10.1016/j.clinthera.2011.07.005 ◽

2011 ◽

Vol 33 (8) ◽

pp. 1096-1103 ◽

Cited By ~ 15

Author(s):

Ulrike Graefe-Mody ◽

Thomas Giessmann ◽

Arne Ring ◽

Mario Iovino ◽

Hans-Juergen Woerle

Keyword(s):

Crossover Study ◽

Healthy Subjects ◽

Relative Bioavailability ◽

Open Label ◽

Effect Of Food

Download Full-text

Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open‐Label Randomized Crossover Study

Clinical Pharmacology in Drug Development ◽

10.1002/cpdd.634 ◽

2018 ◽

Vol 8 (4) ◽

pp. 549-558

Author(s):

Song Ren ◽

David W. Boulton

Keyword(s):

Crossover Study ◽

Healthy Subjects ◽

Pharmacokinetic Interaction ◽

Interaction Study ◽

Open Label ◽

Aluminum Hydroxides ◽

Randomized Crossover Study

Download Full-text